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RESEARCH ARTICLE Open Access
Soluble syndecan-3 binds chemokines,
reduces leukocyte migration in vitro and
ameliorates disease severity in models of
rheumatoid arthritis
Andrew D. Eustace1 , Emily F. McNaughton1, Sophie King1, Oksana Kehoe2, Andreas Kungl3, Derek Mattey4,
Angela H. Nobbs1*, Neil Williams5 and Jim Middleton1
Abstract
Background: Syndecans are heparan sulfate proteoglycans that occur in membrane-bound or soluble forms.
Syndecan-3, the least well-characterised of the syndecan family, is highly expressed on synovial endothelial cells in
rheumatoid arthritis patients. Here, it binds pro-inflammatory chemokines with evidence for a role in chemokine
presentation and leukocyte trafficking into the joint, promoting the inflammatory response. In this study, we explored
the role of soluble syndecan-3 as a binder of chemokines and as an anti-inflammatory and therapeutic molecule.
Methods: A human monocytic cell line and CD14+ PBMCs were utilised in both Boyden chamber and trans-
endothelial migration assays. Soluble syndecan-3 was tested in antigen-induced and collagen-induced in vivo arthritis
models in mice. ELISA and isothermal fluorescence titration assays assessed the binding affinities. Syndecan-3
expression was identified by flow cytometry and PCR, and levels of shedding by ELISA.
Results: Using in vitro and in vivo models, soluble syndecan-3 inhibited leukocyte migration in vitro in response to
CCL7 and its administration in murine models of rheumatoid arthritis reduced histological disease severity. Using
isothermal fluorescence titration, the binding affinity of soluble syndecan-3 to inflammatory chemokines CCL2, CCL7
and CXCL8 was determined, revealing little difference, with Kds in the low nM range. TNFα increased cell surface
expression and shedding of syndecan-3 from cultured human endothelial cells. Furthermore, soluble syndecan-3
occurred naturally in the sera of patients with rheumatoid arthritis and periodontitis, and its levels correlated with
syndecan-1.
Conclusions: This study shows that the addition of soluble syndecan-3 may represent an alternative therapeutic
approach in inflammatory disease.
Keywords: Syndecan-3, Cell migration, Therapeutic, Chemokines, Animal model
Background
Syndecans are heparan sulfate proteoglycans (HSPG)
that consist of a core protein with heparan sulfate (HS)
glycosaminoglycan (GAG) chains covalently attached.
They form part of the glycocalyx network of membrane-
bound proteoglycans and glycoproteins at the endothe-
lial surface, coating the luminal surface of the blood
vessels [1]. There are four members of the syndecan
family [1–4] all of which contain three domains: an
extracellular, transmembrane and cytoplasmic domain.
Extracellular variations exist in the length of the core
protein, as well as the type and number of glycosamino-
glycan chains attached [2]. The intracellular components
contain conserved regions shared by all syndecan family
members but also a variable region thought to interact
with a range of binding partners including kinases,
GTPases and cytoskeletal molecules that may be synde-
can or tissue specific [3, 4].
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In the process of inflammation, HSPGs bound to
endothelial cell (EC) membranes have been shown to
play pro-inflammatory roles [5–7]. In the leukocyte
transmigration cascade, HSPGs stabilise rolling through
interacting with L-selectin, present chemokines on the
endothelial surface (resulting in leukocyte integrin acti-
vation) and are also involved in facilitating chemokine
transcytosis to the luminal endothelial surface [8–13].
There are, however, a number of contrasting studies
using syndecan knockout mice (syndecan-1, syndecan-3
and syndecan-4) in various disease models that also sug-
gest an anti-inflammatory syndecan function [14–16]. A
study by Kehoe et al. identified a dual functionality of
syndecan-3 being pro-inflammatory in the joint and
anti-inflammatory in the skin contributing to the idea
that the syndecan role may be tissue or inflammatory
state specific [16].
Syndecans are also known to be shed from the endo-
thelial surface in a range of chronic inflammatory condi-
tions. It is proposed that shedding can serve a range of
functions including the removal of cells from points of
focal adhesion to the extracellular matrix, removing li-
gands associated with endothelial HS which could create
paracrine effectors, or to release soluble syndecans that
can compete for ligands with their membrane-bound
counterparts [17–20]. While the true function of shedding
may not yet fully be understood, increases in serum con-
centrations of syndecan-1 have been detected in chronic
kidney disease [21], inflammatory bowel disease [22], sys-
temic lupus erythematosus [23] and periodontitis [24]. As
these diseases all involve damage to endothelial surfaces,
an increase in the serum levels could simply represent and
correlate with a disruption or destruction of the glycoca-
lyx. One such inflammatory disease is rheumatoid arthritis
(RA), a chronic, inflammatory, systemic autoimmune dis-
ease affecting approximately 1% of the general population.
Inflammation is central to the RA pathology which can
cause significant disability and mortality, not just through
joint disease manifestation, but also through an increased
association with cardiovascular disease. The hallmark fea-
ture of RA is chronic inflammation of the joint synovium,
characterised by mass infiltration of activated leukocytes
that contribute to progressive destruction of cartilage and
bone. Chemokines play a role facilitating this increase in
infiltration, and as such, their expression levels are natur-
ally found to be elevated in sera, synovial fluid and the
synovium in human RA [25, 26]. A variety of CC and
CXC chemokines are produced by synovial macrophages
and other cell types that attract neutrophils and subse-
quently more long-lived leukocytes. These chemokines in-
clude CCL2, CCL3, CCL5, CCL7, CCL8, CCL13, CCL14,
CCL15, CCL16, CXCL1 and CXCL8 [27]. While the
therapeutic landscape regarding RA treatment has been
positively transformed in the past few decades through
combination therapies of disease-modifying anti-rheumatic
drugs and biologic response modifiers, only 50–60% of RA
patients report long-standing benefits. This figure high-
lights the complexity of RA but also a gap in our under-
standing of the disease and the mechanism required to
develop more effective treatments.
In an attempt to identify which syndecans are respon-
sible for chemokine binding in chronic inflammatory
diseases, Patterson et al. characterised the changes in
HSPG expression in human RA synovium [28]. They
found that not only was there an increase in syndecan-3
expression, but also that there was a selective induction
of a CXCL8 chemokine-binding site on this HSPG on
ECs not present in healthy controls [29]. Furthermore,
in an RA mouse model, syndecan-3 increased leukocyte
accumulation and disease severity [16]. These studies
suggest that membrane-bound endothelial syndecan-3
presents chemokines to the blood leukocyte resulting in
leukocyte migration into the RA synovium. However, lit-
tle is known about the role of soluble syndecans in in-
flammation. That is whether they bind chemokines, alter
chemokine-driven leukocyte migration and if they could
act as competitors and therapeutic agents. The least
characterised in the syndecan family is syndecan-3, first
identified as the predominant syndecan of the nervous
system [30]. It is also known to contribute to cartilage
and skeletal muscle cell differentiation [31] as well as be-
ing implicated in the control of feeding behaviour [32].
The research presented here characterises the role that
soluble syndecan-3 plays in inflammation through ana-
lysing chemokine binding, mRNA and protein expres-
sion; exploring shedding patterns; and in addition,
evaluating the therapeutic potential of soluble syndecan-
3 in vitro and in vivo.
Methods
ELISA
Heparin/GAG binding ELISA plates (Iduron, Manchester,
UK) were used to determine the difference in chemokine
binding to syndecan-3 (R&D Systems, Abingdon, UK) and
HS (Sigma-Aldrich, Dorset, UK). The ELISA was carried
out according to the manufacturer’s instructions. Briefly,
200 μl of HS (25 μg/ml; Sigma-Aldrich) or syndecan-3
(25 μg/ml; R&D Systems) diluted in standard assay buffer
(SAB; 100mM, 50mM sodium acetate, 0.2% v/v Tween
20) were added to wells in the GAG binding microplate
overnight. Plates were washed with buffer and blocked
with blocking solution (PBS/1% bovine serum albumin,
BSA). A dilution series for the chemokine CCL7 (from 0
to 3 μg) was generated, and 200 μl was added to the wells
for 2 h. Plates were washed with buffer and incubated with
200 μl of biotinylated anti-CCL7 (250 ng/ml; Peprotech)
for 1 h. Plates were washed again and incubated with
200 μl of ExtrAvidin-alkaline phosphatase (4 μg/ml;
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Sigma-Aldrich) for 30min. They were washed a final time,
and development reagent was added (SigmaFAST p-
Nitrophenyl phosphate) for 40min before optical densities
were read at 405 nm on a microplate reader. OD405 read-
ings from a blank well with no syndecan-3 or HS were
subtracted from each test sample to correct for back-
ground OD interference. OD was plotted against CCL7
concentration to give two standard curves.
In a separate assay, TNFα-supplemented medium used
to stimulate hBMECs was also tested for human
syndecan-3 by ELISA (R&D Systems) in accordance with
the manufacturer’s protocol. Control medium with no
TNFα (DMEM-F12/0.5% FBS) and TNFα-supplemented
medium [100 ng/ml] were incubated with hBMECs for
1, 2, 6 and 24 h.
Isothermal fluorescence titration
Isothermal fluorescence titration (IFT) was used to study
the binding affinity of syndecan-3 and HS to CCL2,
CCL7 and CXCL8. The technological principle is based
on the reduction in fluorescence (quenching) of intrinsic
tryptophan amino acids within each chemokine when
syndecan-3 binds as described elsewhere [33]. Titration
experiments were performed on a Fluoromax-4 Spectro-
fluorometer (Horiba, Kyoto, Japan). Protein fluorescence
emission spectra were recorded over the range of 300–
400 nm with excitation at 295 nm. Slit widths were set at
4 nm + 4 nm for excitation and emission. The use of
concentrated GAG oligosaccharide/syndecan-3 stock so-
lution ensured a dilution of the protein sample less than
5%. Chemokine (CCL2, CCL7 and CXCL8) solutions
(700 nM) were prepared from stock solutions and
needed to be equilibrated for 30 min in PBS. Respective
ligands (syndecan-3, HS) were added in 20 nM concen-
trations until maximum quenching was reached corre-
sponding to saturation of all binding sites. The
chemokine solutions were equilibrated for 1 min, and
fluorescence emission spectra were collected. For back-
ground correction, the emission spectra of the respective
ligand concentrations were collected in PBS buffer only.
They were subsequently subtracted from the protein
emission spectra and divided by the value given at the
added HS concentration. Values from this equation were
averaged from three independent experiments and
plotted against HS concentration [33]. The resulting
binding isotherms were analysed by nonlinear regression
to give a Kd using the program Origin (Microcal Inc.,
MA, USA).
Cell culture
For in vitro migration assays and mRNA and protein ex-
pression analysis, immortalised human bone marrow
endothelial cells (hBMEC) donated by Prof. BB Weksler
[34] were utilised. These cells express relevant adhesion
molecules and support leukocyte trans-endothelial mi-
gration [35]. Cells were maintained in DMEM-F12
(Lonza Ltd., Slough, UK) containing 10% FBS (Sigma-Al-
drich) at 37 °C in 5% CO2 atmosphere and grown to
around 70% confluence before being used in experi-
ments. The human monocytic cell line (THP-1) was
grown in RPMI-1640 (Sigma-Aldrich) supplemented
with 10% FBS (Sigma-Aldrich). Cells were split at a 3:1
ratio once they had exceeded a density of 1 × 106 cells/
ml. PBMCs were isolated from healthy volunteers via
Polymorphprep separation technique (Axis-Shield Diag-
nostics Ltd., Dundee, UK).
Chemotaxis
Two different chemotaxis systems were utilised, both
operating with a two-chamber system: 48-well micro
chemotaxis Boyden chamber (Neuro Probe, Inc., MD,
USA) and the 96-transwell system (Corning Ltd., Flint-
shire, UK) with the latter containing a hBMEC mono-
layer between the chambers.
Boyden chamber chemotaxis
RPMI (100 μl) supplemented with 1% BSA was added to
both upper and lower chambers of the Boyden chamber
and allowed to block for 30 min before being removed.
Twenty-eight microlitre of CCL7 (100 ng/ml; optimum
concentration was ascertained from adding 0.01–500 ng/
ml CCL7 in separate Boyden chamber experiments; data
not shown) or RPMI alone (negative control) was added
in triplicate to the basal chambers with an 8-μm polycar-
bonate filter applied on top. The upper chamber was
then attached. THP-1 cells (50 μl) at a concentration of
1.6 × 106 cells/ml were added to the upper chamber for
an incubation time of 3 h at 37 °C and 5% CO2
atmosphere.
After 3 h, the suspensions in the upper chambers were
removed and the top of the filter was wiped gently.
Cells/media in the bottom chamber were then counted
using a haemocytometer (Immune systems Ltd., Devon,
UK). Migrated cells were identified as those within the
basal chamber media, and migration was calculated as
a percentage of the positive control. The method used
here is a modified version of a previously described
assay [36].
Further experiments saw the addition of syndecan-1,
syndecan-2, syndecan-3 or syndecan-4 (R&D Systems)
to the lower chambers with the chemokine to determine
any pro- or anti-migratory effects. Syndecan concentrations
ranged from 0.01 to 100 μg/ml.
Endothelial transmigration
3.2 × 104 ECs were seeded onto 96-well chamber
membranes (Corning Ltd.) in DMEM-F12/10% FBS. The
confluence of the monolayers was tested via trans-
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endothelial electrical resistance (TEER). After 24 h (at
peak resistance), adhered cells were washed gently with
warm PBS twice. Two hundred thirty-five microlitre of
CCL7 (100 ng/ml) was added to the basal chamber. The
apical chamber was filled with 1 × 105 human PBMCs in
100 μl DMEM-F12/0.5% FBS and allowed to migrate for
3 h at 37 °C CO2 atmosphere. Migrated cells were classi-
fied as those which had migrated to the bottom cham-
ber. These cells were then diluted with trypan blue
(Sigma-Aldrich) and counted using a haemocytometer.
Once again, further experiments saw the addition of
syndecan-3 (0.1–50 μg/ml; R&D Systems), syndecan-3
core protein (a gift from Dr. James Whiteford, University
of Queen Mary, University of London, UK) and HS
chains (Sigma) to the lower chambers with CCL7 to de-
termine their effects.
Animals
Antigen-induced arthritis (AIA) experiments were
undertaken on 8-week-old inbred male C57BL/6JOlaHsd
wild-type mice (Harlan Laboratories Ltd., Bicester, UK).
Procedures were conducted in accordance with Home
Office Project Licence PPL40/3594 in collaboration with
Personal Licence holder Dr. Oksana Kehoe at Liverpool
John Moores University.
Collagen-induced arthritis (CIA) experiments were
conducted on adult male DBA/1 wild-type mice (Charles
River, Oxford, UK) in accordance with Home Office
Project Licence PPL 30/3097 by KWS Biotest, Bristol, UK.
Injection of syndecan-3 in mice
Antigen-induced arthritis
Murine AIA was induced as previously described [37].
Mice were immunised subcutaneously with 1 mg/ml of
mBSA emulsified with an equal volume of Freund’s
complete adjuvant (CFA) via intraperitoneal injection
with 100 μl (160 ng) heat-inactivated Bordetella pertussis
toxin in PBS. The immune response was boosted 1 week
later with the same amount of mBSA as before. Twenty-
one days after the initial immunisation, murine AIA was
induced by intra-articular (IA) injection of 10 mg/ml
mBSA in PBS in the right knee (test) joint. For a control,
the same volume of PBS was injected into the left knee
joint at the same time points.
Human syndecan-3 (5 μg; R&D Systems) in 10 μl PBS
(500 μg/ml final concentration) was injected into the
right knee joints at day 1 post-arthritis induction at peak
joint swelling. A control group was injected with PBS
alone at the same time point. Eight mice were randomly
assigned to either the control (PBS injection) or test
(syndecan-3 injection) group, and 4 from each group
were sacrificed on day 3 and day 7 post-syndecan-3 in-
jection. The dosing rationale was based on previous IA
injections of a GAG-binding peptide that reduced joint
swelling in the same mice (unpublished data).
Collagen-induced arthritis
CIA was induced as previously described [38]. On day 0,
a subcutaneous injection was administered of 100 μl of
an emulsion containing 100 μg of CII (type II collagen) in
complete Freund’s adjuvant supplemented with 4mg/ml
Mycobacterium tuberculosis H37Ra. On day 21, animals
received a subcutaneous injection with a booster emul-
sion containing 100 μg of CII in incomplete Freund’s
adjuvant (IFA). Animals were treated according to the
syndecan administration schedule below at days 21, 24,
29, 34, 39 and 44.
The results obtained from the AIA model were used
as a starting point for intravenous (IV) injections in the
CIA model. The effects observed in the AIA model came
after a 5-μg injection into the IA space. The decision
was made in CIA to administer 7 μg on 6 occasions
every 3–4 days post-peak swelling, based on syndecan-3
being injected into the bloodstream as opposed to the
smaller volume of the IA space. The administration vol-
ume for IV injection was 5 ml/kg. DBA/1 mice weighed
approximately 20 g meaning an administration volume
of 100 μl syndecan-3 in PBS (70 μg/ml final concentra-
tion; n = 10). Control animals (n = 10) were injected with
100 μl PBS. At termination (day 45), the hind limbs were
dissected and stored in formaldehyde.
Histological assessment
The knee joints (AIA) and hind paws (CIA) were re-
moved and fixed in neutral buffered formal saline.
Decalcification in formic acid, embedding in paraffin
and sectioning were carried out by the histology depart-
ment RJAH Orthopaedic Hospital (Oswestry, UK). Mid-
sagittal serial sections (5 μm thickness) were cut and
stained with haematoxylin and eosin (H&E) or toluidine
blue. The sections were scored blind by two independent
observers from 0 to 3 based on the severity of hyperpla-
sia of the synovial lining layer, synovial exudate in the
joint space and cartilage GAG depletion or 0–5 for syn-
ovial expansion as described in earlier AIA studies [16].
An additional parameter of pannus invasion being
scored from 0 to 3 was used when assessing CIA. All
scores were combined generating an arthritis index.
Immunofluorescence
Unstained AIA knee sections were dewaxed in xylene
twice for 5 min, rinsed in IMS twice for 2 min and rehy-
drated in distilled water for 5 min. Antigen retrieval was
then carried out via immersion in 10 mM Tris buffer
HCL (pH 9) overnight at 50 °C, and the slides were then
washed in PBS.
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The sections were stained with anti-CCL7 (R&D Systems;
10 μg/ml, goat anti-mouse, IgG) in PBS for 1 h. The slides
were washed in PBS 3 times, and 200 μl of Alexa-594
donkey anti-goat IgG1 (1:200 dilution in PBS/10% mouse
serum; Invitrogen) for a further 1 h. Cells were washed
again 3 times in PBS and stained with 200 μl DAPI (2 μg/
ml in PBS; Invitrogen) for 3min before being washed in
PBS for 5min, rinsed in distilled water, air dried and
mounted with Hydromount (Thermo Fischer Scientific).
Flow cytometry
Flow cytometry was used to characterise syndecan-3
protein expression in response to TNFα. hBMECs were
grown in chamber slides and stimulated with or without
TNFα for 24 h (Peprotech EC Ltd., London, UK; 100 ng/ml
in DMEM-F12, 10% FBS). Cells were harvested using cell
dissociation buffer (Sigma-Aldrich) to ensure that extracel-
lular proteins remained intact. To ascertain extracellular
expression, one population of cells was blocked with FcR
blocking agent in FACS buffer (Thermo Fisher Scientific,
Loughborough, UK) and stained with anti-syndecan-3
(APC; 25 μg/ml; R&D Systems) or an isotype control
(APC; 25 μg/ml; Thermo Fisher Scientific Ltd.) antibody
and fixed according to the manufacturer’s protocol (FIX&-
PERM, Thermo Fisher Scientific). To determine intracellu-
lar expression, a duplicate population was blocked, stained
with anti-syndecan-3, fixed, permeabilised and stained
again according to the protocol. The level of expression
from this population was subtracted from the non-
permeabilised population. Both populations of cells were
washed in FACS buffer, re-suspended in 1% PFA and
stored at 4 °C prior to flow cytometry. Data are expressed
as a median fluorescence intensity.
mRNA expression of syndecan-3
To characterise syndecan-3 gene expression in response
to an inflammatory stimulus, hBMECs were cultured in
the presence of TNFα. hBMECs were grown in 8-well
chamber slides (Thermo Fischer Scientific) in DMEM-
F12/0.5% FBS alone or supplemented with TNFα [100
ng/ml] for 0, 1, 2, 6 and 24 h. RNA (~ 100 μg) was ex-
tracted from 3–4 × 105 hBMECs using RNeasy mini kit
(Qiagen, Hilden, Germany). Approximately 6–8 μg RNA
was converted to cDNA using iScript cDNA synthesis
kit (Biorad Laboratories Ltd., Hertfordshire, UK) accord-
ing to the manufacturer’s instructions. Controls con-
tained no RNA. The mRNA expression levels of relevant
genes (syndecan-3 and glyceraldehyde 3-phosphate de-
hydrogenase; GAPDH) were quantified by real-time PCR
using SYBR green supermix (Biorad) and read via a
Chromo-4 Detector (Biorad) with primers as published
elsewhere [29]. The sequences for syndecan-3 were
ACCCCAACTCCAGAGACCTT (forward) and CCCA
CAGCTACCACCTCATT (reverse); the specific primers
for GAPDH were GAGTCAACGGATTTGGTCGT (for-
ward) and GACAAGCTTCCCGTTCTCAG (reverse).
The total volume per well was 20 μl, containing 1–3 μg
cDNA (100 fg–100 ng), 10 μl SYBR green and 0.8–
1.16 μl (300 nM) forward and reverse primers (Eurofins
Genomics, Ebersberg, Germany), with PCR water mak-
ing up the final 20 μl volume as listed below.
Syndecan-3 mRNA expression was analysed in re-
sponse to TNFα at time points 1, 2, 6 and 24 h. CT
values obtained for the reference gene GAPDH at each
time point were subtracted from syndecan-3 gene ex-
pression to generate ΔCT. The ΔCT control values (in
the absence of TNFα) were then subtracted from TNFα-
stimulated samples (ΔΔCT). These were then trans-
formed to create 2−ΔΔCT. CT values were subtracted
from the reference gene (GAPDH) for at each time
point. The resulting control values at each time point
were then subtracted from the TNFα-stimulated values,
of which a ratio was calculated via 2−ΔΔCT.
Detection of syndecan-1 and syndecan-3 in human blood
RA patient serum collected from the Haywood Hospital
in collaboration with Dr. Derek Mattey was analysed
using syndecan-1 and syndecan-3 ELISA Duoset kits
(R&D Systems) according to the manufacturer’s instruc-
tions. In addition, blood serum samples were taken from
patients attending the Bristol Dental School clinic with a
diagnosis of periodontitis.
Statistics
All statistical analyses were performed using GraphPad
Prism software (San Diego, CA). To determine statistical
significance, Mann-Whitney U tests were performed on
histological and ELISA data, excluding the ELISA data
collected from culture media which was analysed via
Student’s t test. The CCL7 ELISA was also analysed by t
test and a two-way ANOVA with Sidak’s multiple com-
parisons post-test. Pearson’s correlation coefficient was
used to analyse syndecan-1 and syndecan-3 correlation.
One-way ANOVA with Tukey post-test CT values were
used when analysing mRNA data. For Boyden chamber
and trans-endothelial migration results, an ANOVA with
a Dunnet post-test was performed.
Results
Chemokines bind to soluble syndecan-3, comparison with HS
In an attempt to further the work carried out by
Patterson et al. on syndecan-3 chemokine binding on
ECs in the RA synovium [28, 29], we tested the binding
affinities of clinically relevant chemokines to commer-
cially sourced soluble syndecan-3 using IFT. Binding af-
finities (Kd) between chemokines CCL2, CCL7and
CXCL8 and syndecan-3 were in the low nM range and
were similar (Fig. 1a, b; Table 1). Chemokine affinities
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varied more when binding to HS with the order being:
CCL7>CXCL8>CCL2. A major difference was the re-
duced affinity of CCL2 for HS compared to syndecan-3
(over fivefold; Fig. 1a, b; Table 1). The results obtained
from coating specialised ELISA plates with syndecan-3
and HS also showed chemokine binding (Fig. 1c), and
taking the data overall, CCL7 binding was not signifi-
cantly different between the two molecules. At lower
and physiological CCL7 concentrations (< 1 μg/ml), the
optical densities for syndecan-3 and HS were also not
significantly different; however, at high concentrations
(1.5 and 3 μg/ml), HS bound more chemokine (P < 0.05
and P < 0.01 respectively).
Soluble syndecan-3 decreases levels of THP-1 and PBMC
migration in vitro
To characterise the role of shed syndecans in inflamma-
tion, soluble syndecans 1–4 were individually added to in
vitro migration assays. In the Boyden chamber, the
addition of only syndecan-3 to the basal chamber signifi-
cantly reduced the levels of monocyte (THP-1) migration
in response to CCL7 (ANOVA P < 0.0001; Fig. 2a). The
maximum inhibitory effect was at 10 μg/ml (P < 0.0001).
At this concentration, there was no significant difference
to baseline migration levels. No other member of the syn-
decan family produced such an effect at any concentration
(up to 100 μg/ml); in addition, there were no significant
effects of syndecan-1, syndecan-2, syndecan-3 or
syndecan-4 on CCL2-stimulated THP-1 cell migration.
The same significant inhibitory effect was observed in
the more complex endothelial transmigration assay
using PBMCs at a syndecan-3 concentration of 1, 10 and
50 μg/ml (P < 0.01, P < 0.001, P < 0.01 respectively;
Fig. 2b). In an attempt to understand the functionality of
syndecan-3, the individual components (syndecan-3 core
protein and HS chains) were added individually to the
basal chamber with CCL7 to observe which had an ef-
fect. Figure 2c shows that the individual components did
not elicit the same level of response as the intact
syndecan-3 (P > 0.0001). The condition that mimicked
intact syndecan-3 most closely was when HS was added
at 250 μg/ml (P < 0.001); however, this was calculated to
A
B
C
Fig. 1 Chemokines bind to soluble syndecan-3 and heparan sulfate
(HS). Isothermal fluorescence titration (A+B). a HS binding isotherms
of CCL2 (black squares), CCL7 (red circles) and CXCL8 (blue
triangles). b Syndecan-3 binding isotherms of the same chemokines.
For Kd values, see Table 1. The y-axis shows the relative change in
fluorescence intensity following ligand addition: ΔF = F (fluorescence
emission at a certain ligand concentration) − F0 (fluorescence
emission in the absence of ligand). c Syndecan-3 and HS were
coated onto GAG microplates overnight [25 μg/m]. A dilution series
of CCL7 was added to the plates to identify the level of binding.
Plates were read at 405 nm. Data points represent means ± standard
error (n = 3 separate experiments)
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be approximately 5 times the amount as present on the
intact syndecan-3. The core protein and HS at 10 μg/ml
elicited less significant reductions in migration (P < 0.05
and P < 0.01 respectively).
Administration of soluble syndecan-3 reduces disease
severity in animal models of RA in vivo
To identify any effects in biological systems of inflam-
mation, soluble syndecan-3 was administered in two in-
flammatory mouse models. In the first model (AIA), an
intra-articular injection of soluble syndecan-3 signifi-
cantly reduced overall histological parameters of disease
as measured by an arthritis index in comparison with an
intra-articular injection of PBS (P = 0.04: Fig. 3a–e). To
ascertain whether the injected syndecan-3 reduced the
expression of CCL7 in the blood vessels, histological sec-
tions were stained with anti-CCL7. The joints injected
with syndecan-3 contained significantly reduced levels of
CCL7 in the blood vessels in comparison with those
injected with PBS (P = 0.011; Fig. 3f–j). In the second
inflammatory model (CIA), multiple intravenous (IV) in-
jections were also sufficient to significantly reduce histo-
logical parameters of disease as measured by the arthritis
index (P = 0.045; Fig. 3e). Individually, the histological
scores of intimal hyperplasia were significantly reduced
after syndecan-3 injections (P = 0.0005; Fig. 3e) whereas
other individual scores were reduced but not significantly.
Exposure to TNFα increases endothelial syndecan-3
surface expression and shedding
To further characterise the role of syndecan-3 in inflam-
mation, hBMECs were stimulated with TNFα for 24 h.
The culture medium was analysed for soluble syndecan-
3, and cellular syndecan-3 mRNA and protein were also
analysed. Over 24 h, the rate of syndecan-3 shedding
significantly increased (ANOVA P < 0.05; Fig. 4a) in re-
sponse to TNFα stimulation, being elevated at 6 and 24
h. Over the same time course, the level of intracellular
syndecan-3 protein expression reduced by approximately
20% (P < 0.01) while the surface expression increased by
the same value (P < 0.01; Fig. 5b). The difference
between intracellular and cell surface expression was
maximal at 24 h (P < 0.001). The level of mRNA expres-
sion in response to TNFα over 24 h did not change
(Additional file 1: Table S1).
Syndecan-3 is shed in human serum
To find out if shed syndecan-3 occurs in vivo in chronic
inflammatory disease, sera were collected from patients
with RA and periodontitis and analysed by ELISA.
Syndecan-3 was detected in both patient groups, and
significantly more was present in the sera of RA patients
in comparison with those with periodontitis (P = 0.004;
Fig. 5a). The median syndecan-3 level was 2219 pg/ml in
RA and 220 pg/ml in periodontitis. A significant positive
linear correlation was observed between the levels of
shed syndecan-1 and syndecan-3 in RA patient sera
(correlation coefficient r = 0.76; P < 0.0001; Fig. 5b).
Discussion
This current study has attempted to further characterise
the role that soluble syndecan-3 plays in inflammation
as well as explore the possibility of using it as a thera-
peutic agent. Membrane-bound HSPGs on ECs bind
chemokines and participate in leukocyte extravasation
by influencing the transport of chemokines across the
endothelium and presenting them to the blood leuko-
cytes [8, 10, 12]. Here, we show that soluble syndecan-3
also has the potential to bind to both CC and CXC che-
mokines involved in the above roles. Our IFT data reveal
little difference in the affinity (Kd) between the chemo-
kines CCL7, CCL2 and CXCL8 and their interaction
with syndecan-3. While the chemokine binding to
syndecan-3 was similar to HS, some variation was
present for CCL2 which showed lower affinity for HS
compared to syndecan-3. Chemokine binding to heparin,
HS and other GAGs has been well documented [17, 39–
42]. However, to our knowledge, this is the first study to
characterise the chemokine-binding affinity of a HSPG,
which by definition contains GAG chains covalently at-
tached to a core protein, representing how most GAGs
occur in the body.
In addition to the roles already attributed to the shed-
ding of syndecans, as stated in the introduction, we pro-
posed an anti-inflammatory mechanism whereby shed
syndecan-3 can compete for chemokines limiting their
availability to recruit inflammatory cells. In a study by
Xu et al. [14], endogenously shed syndecan-1 bound to
inflammatory chemokines (CCL7, CCL11, CCL17) at-
tenuating allergic lung inflammation through inhibiting
chemokine mediated T cell migration. Combining this
Table 1 Isothermal fluorescence values for CCL2, CCL7 and CXCL8 binding to HS and syndecan-3. Isothermal fluorescence values
are expressed as dissociation constants (Kd) with standard error of the mean
Heparan Sulfate (HS) Syndecan-3
Kd (nM) ± (SEM) Kd (nM) ± (SEM)
CCL2 508 32 94 20
CCL7 109 8 143 14
CXCL8 145 6 184 22
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finding with a tissue’s potential to induce chemokine-
binding sites on specific syndecans led to the idea of
testing of their anti-inflammatory potential in vitro and
in vivo. From the commercially available syndecans, only
syndecan-3 elicited anti-inflammatory effects on mono-
cytic cells and PBMCs in two chemotactic assays in a
dose-dependant manner. We propose that soluble
syndecan-3 binds to free chemokines and selectively in-
terferes with GPCR-chemokine binding depending on
the receptor ligand affinity. This would result in less
leukocyte transmigration. Soluble syndecan-3 may there-
fore be acting as a competitor, trap or decoy molecule in
a strategy utilised by the body to further regulate the in-
flammatory response. Our chemotactic assay concerning
individual syndecan-3 components revealed an enhanced
effect of the core protein and the HS chains being
present together in the HSPG molecule, whereby to-
gether, a stronger anti-migratory response was observed
than individually. Reasons as to why syndecan-3 was the
only syndecan in the family to elicit significant reduc-
tions in migration could relate to the length of the HS
chains, as those of syndecan-3 are the longest, as calcu-
lated from the molecular mass and size from SDS-PAGE
(R&D Systems website). Kuschert et al. [17] identified a
relationship through solid-phase binding assays whereby
chemokine affinity positively correlates with HS chain
length. This explanation suggests therefore that the lon-
ger syndecan-3 HS chains are more successful in binding
chemokines and interfering with the chemokine-GPCR
complex. This theory does not however factor in the im-
portant intricacies of the GAG chain make-up. This is
something that is widely reported as being hugely influ-
ential in determining affinities. However, as all our com-
mercially acquired syndecans were synthesised in the
same cell type (mouse myeloma cell line, NSO-derived),
and that current understanding of chain composition
and polymerisation is dependent on the HS enzymes
present in the cell’s Golgi bodies at the time of synthesis,
one would postulate the GAG composition to be com-
parable. Syndecan-3 is also known to host chondroitin
sulfate chains on the core protein; however, previous re-
ports have highlighted lower chemokine affinities than
HS [17, 42].
It needs to be mentioned that endogenously produced
syndecans under normal or inflammatory conditions can
be modified, for example, in the endothelial cells in RA
[29]. The present study uses commercially produced
syndecans expressed in mouse myeloma cells, so it is
possible that these may contain modifications different
from those occurring in vivo.
More recent evidence suggests that chemokine-GAG
interactions are more complex than first thought. There
are two ways that syndecan-3 may be inhibiting mono-
cyte migration in vitro. Firstly, syndecan-3 may be
Fig. 2 Anti-migratory effects of syndecan-3 in vitro. a Migration of
THP-1 cells to CCL7 (100 ng/ml) with increasing amounts of
syndecan-3 in a Boyden chamber chemotaxis assay. The stars
represent a significant ANOVA with Dunnett’s post-test (*P < 0.05,
**P < 0.01, ****P < 0.0001). b The same assay was carried out using
PBMCs and migration across endothelial cell-coated 96-well inserts.
The stars represent a significant ANOVA with Dunnett’s post-test
(**P < 0.01, ****P < 0.0001). c The 96-well format was used to help
identify the functional components of syndecan-3 whereby the core
protein and HS chains were added individually. Intact syndecan-3
and the syndecan-3 core protein were added at 10 μg/ml. Heparan
sulfate was added at 50 and 250 μg/ml as indicated. The stars
represent a significant ANOVA with Dunnett’s post-test (*P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001). For a–c, the columns
represent mean values, with standard errors (n = 3 separate
experiments performed in triplicates). Results are displayed as a
percentage of the positive control. S3, syndecan 3; S3CP, syndecan 3
core protein; HS10, heparan sulfate at 10 μg/ml; HS250, heparan
sulfate at 250 μg/ml. In all experiments, CCL7 [50 ng/ml] was added
to all but the negative control (−). The positive control contained
chemokine alone (+)
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simply sequestering CCL7. Secondly, CCL7 interaction
with syndecan-3 may be interfering with its ability to
bind to its high-affinity GPCR receptors [43–45]. Since
the ability of HS to bind CCL7 was overall not signifi-
cantly different from that of intact syndecan-3 (Fig. 1c),
their ability to sequester CCL7 was broadly similar. In
addition, the presence of the core protein within
syndecan-3 enhanced the inhibitory effect on monocyte
migration more effectively than HS in vitro (Fig. 2c),
suggesting that this HSPG may also be interfering with
the ability of CCL7 to bind to its GPCR chemokine re-
ceptors on monocytes.
In our two in vivo models of inflammation, the
addition of soluble syndecan-3 had therapeutic effects
reducing the overall disease severity. This may relate to
the reduction in CCL7 staining in the synovial vascula-
ture by syndecan-3, reducing the expression of the che-
mokine by/on the endothelial cells, which in turn could
reduce disease severity. In RA pathology, there is thick-
ening of the synovial intimal layer largely due to in-
creased macrophage numbers [46, 47]. These are
recruited as monocytes from the synovial blood vessels
and migrate to the intimal layer where they accumulate.
The finding that the addition of soluble syndecan-3 re-
duces intimal layer thickening in CIA may be related to
reduced recruitment of monocytes due to this HSPG-
binding chemokines like CCL7. However, further experi-
ments showing syndecan-3 binding CCL7, and other
mediators, in vivo are warranted to confirm this inter-
action which was shown in vitro by our IFT and ELISA
binding data and migration assays.
It is evident that conflicting reports of the effects of
syndecans, soluble or membrane-bound, do exist in the
literature, whereby some appear pro-inflammatory while
others appear anti-inflammatory. This disparity is likely
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Fig. 3 Therapeutic effects of syndecan-3 in the antigen-induced
arthritis (AIA) and collagen-induced arthritis (CIA) mouse models.
Histological sections were analysed for any effects on inflammation
and tissue damage after a syndecan-3 intra-articular injection.
Parameters measured for AIA were a thickening of the synovium*, b
exudate in the joint space (arrow) with insert showing higher
magnification, c hyperplasia of the synovial lining layer (arrow) and
d loss of proteoglycans from articular cartilage (arrow showing loss
of toluidine blue staining). The histological scores for 3 days post-
injection are displayed in e (means and standard errors are shown,
n = 4 mice in each group for AIA and n = 10 mice for CIA; *P < 0.05;
*** P < 0.001; AI, arthritis index). f, g Blood vessels positive for CCL7
in the control (PBS injected) AIA group. h, i Blood vessels negative
for CCL7 staining in the test (syndecan-3 injected) AIA group, as
indicated by arrows. g, i Merged DAPI images. j Five random fields
of view per mouse scored based on the percentage of the blood
vessels positive for CCL7 staining on synovial endothelial cells after
PBS (control) or syndecan-3 intra-articular injection (data are means
with standard errors, n = 7 AIA mice per group; *P < 0.05). The
magnification bars in a–d represent 200 μm and f–i 50μm
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attributed to the tissues in which syndecans are
expressed or type of inflammation. Kehoe et al. report a
pro-inflammatory membrane-bound syndecan-3 in the
synovium, yet it is anti-inflammatory in the skin and cre-
master muscle [16]. Furthermore Li et al. also report a
pro-inflammatory function of a shed syndecan-1 binding
CXCL8, directing migration and confining neutrophils
to the sites of lung injury. It is apparent therefore that
syndecans may play various paradoxical roles depending
on the tissues in which they are expressed, whether they
are membrane-bound or soluble and finally what physio-
logical state the tissues are in. Our study highlights the
potential merit of utilising syndecans as a novel thera-
peutic intervention strategy; however, further work is
required to realise the limitations including any potential
tissue-specific effects, dose efficacy, half-life and the
merits of various administration routes.
In the current study, two routes of syndecan-3 injection
were used: IV and intra-articular. CIA is a systemic model
of RA involving more than one joint; therefore, it was de-
cided that IV route of injection would be appropriate.
Whereas the AIA model affects one joint (the knee);
therefore, it was considered more relevant to inject synde-
can locally by intra-articular administration. It was of
interest to compare these two routes of administration,
and both had positive effects on disease outcome.
Research by Patterson et al. has already revealed an in-
duced chemokine-binding site on endothelial syndecan-
Fig. 4 Effects of TNFα on syndecan-3 shedding. a Endothelial cells were treated with or without TNFα [100 ng/ml] supplemented media for up to
24 h. The media was then subjected to an ELISA to detect syndecan-3. The graph depicts TNFα-stimulated shedding values minus those of
controls in the absence of TNFα at each time point. The bars represent mean values with standard errors (n = 3 independent experiments). The
stars represent a significant ANOVA followed by Tukey post-test (P < 0.05). b Again, endothelial cells were cultured with and without TNFα-
supplemented media. This time, the level of intracellular and extracellular syndecan-3 was assessed via flow cytometry in comparison with cells
treated with control media. Data points represent percentage change of cells positive for syndecan-3 intracellularly or on the extracellular surface
(fluorescence intensity; means with standard errors; n = 3 independent experiments). The three stars represent a significant two-way ANOVA
(without repeated measures) with Tukey post-test (***P < 0.001) depicting a highly significant difference between intracellular and extracellular
expression at 24 h. The plus symbol represents significant differences (via one-way ANOVA with Tukey post-test) within the extra- and intracellular
expression profiles at 24 h (++P < 0.01)
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3 in the RA synovium which was not present on the
other syndecans within the tissue. This suggests that
ECs are capable of modifying the chemokine-binding af-
finity of syndecans under different physiological states,
most likely through altering the activity of NDST en-
zymes which has already been documented for other
syndecans in different tissues and diseases [48, 49]. Here,
we show in vitro that in response to the inflammatory
stimulus TNFα, intracellular syndecan-3 stores are trans-
ported to the EC surface while, at the same time, in-
creasing levels of syndecan-3 are shed from the EC
surface to the surroundings. We hypothesise that this is
a potential mechanism to introduce more or replace syn-
decans on the EC surface with higher affinity HSPGs for
chemokines, resulting in higher levels of leukocyte re-
cruitment. In contrast, the shed syndecan-3 could act as
an anti-inflammatory effector by binding chemokines
and limiting their pro-migratory activity.
Finally, the results showed that shed syndecan-3 does
occur in vivo in the human autoimmune/inflammatory
conditions of RA and periodontitis. Furthermore, differ-
ences appear to exist between inflammatory diseases sug-
gesting the potential of syndecans to be diagnostic markers
of diseases. RA levels of shed syndecan-3 are tenfold higher
than in periodontitis. Since chemokine levels are elevated
in the serum of RA patients, it is possible that syndecan-3
binding is saturated and addition of exogenous syndecan-3
could bind further free chemokines and limit their ability of
recruiting leukocytes to inflamed sites. In addition,
syndecan-3 is particularly expressed in joint tissues and
with multi-joint involvement in RA it might be expected
that shed levels to be higher in the serum. Whereas in peri-
odontitis, the disease is more site-specific, being the gingiva
that is involved. In periodontitis, the lower levels of
syndecan-3 suggest other types of syndecans may be shed,
reflecting different expression profiles between inflamed tis-
sues [24, 28]. In addition, there may be positive relation-
ships between syndecans in terms of biomarkers since the
levels of syndecan-3 and syndecan-1 correlated in RA sera.
Conclusions
This study characterises the binding of chemokines to
soluble syndecan-3 and shows this soluble HSPG in-
hibits leukocyte migration in vitro and reduces disease
severity in animal models of RA. Therefore, soluble
syndecan-3 may have potential therapeutic effects in
inflammatory diseases like RA.
Additional file
Additional file 1: Table S1. Effects of TNFα on endothelial cell syndecan-3
RNA gene expression. Endothelial cells were treated with and without TNFα
[100 ng/ml] for up to 24 h and RNA subjected to quantitative PCR. An ANOVA
with Dunnet post-test did not give any significant differences between time
points. (PDF 130 kb)
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